CONCLUSION
For DDC c.19C>T (p.Arg7Ter), intracerebral AAV2-mediated DDC gene replacement is a strong therapeutic match because the variant is an early nonsense change and the approved treatment logic is gene addition, not allele-specific rescue. In practice, that makes this variant a good conceptual fit for Upstaza-style therapy if the clinical phenotype and treatment access line up.
EVIDENCE
c.19C>T creates a very early stop codon and ClinVar classifies the variant as pathogenic for aromatic L-amino acid decarboxylase deficiency. Eladocagene exuparvovec (Upstaza) is an EMA-authorized AAV2 gene therapy for AADC deficiency, and long-term follow-up published in Molecular Therapy showed sustained motor and cognitive gains with durable safety observations after bilateral putaminal administration. Because the treatment delivers a functional DDC cassette directly to the target brain region, the biological rationale does not depend on repairing this exact nonsense allele.
LIMITATIONS
The main limitation is procedural and anatomic rather than allelic: benefit depends on neurosurgical delivery to the putamen, experienced centers, and enough surviving neural substrate to respond. The strongest evidence is disease-level rather than variant-level, and very early truncating variants such as p.Arg7Ter may still present with severe baseline disease that limits the magnitude of functional recovery even if enzyme activity is restored. Long-term comparative data against best supportive care remain limited, and access is highly concentrated geographically.
I would favor the gene-therapy framing here over targeted editing for a simple reason: there is already a clinically validated route that bypasses the need to design a bespoke editor for one ultra-rare stop-gain allele. The caveat is that AADC deficiency outcomes are tightly linked to timing and baseline neurologic status, so this variant should not be interpreted as guaranteeing the same degree of recovery seen across mixed cohorts.